The Latest Cardiac and Vascular News
SOUTH SAN FRANCISCO, Calif. and OAKLAND, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) and the American Heart Association (AHA) Bay Area today announced a three-year collaboration to accelerate education and awareness of heart disease. Within the collaboration, Cytokinetics will provide funding and support for several initiatives […]
Fourth Quarter 2021 Revenue of $3.7 million, a 75% Increase Over Prior Year MINNEAPOLIS, Feb. 15, 2022 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results […]
– Phase 1/2 clinical trial expected to initiate in mid-2022 – – LX2006 is the first clinical-stage program from LEXEO’s cardiovascular pipeline and the third clinical-stage gene therapy candidate across its pipeline – NEW YORK, Feb. 16, 2022 (GLOBE NEWSWIRE) — LEXEO Therapeutics (LEXEO), a clinical-stage gene therapy company advancing a diverse […]
Cardiovascular disease (CVD), a leading cause of death and disability worldwide, involves structural and functional changes in the heart Local sterile inflammation by the innate immune system results in a signalling cascade, particularly activation of NLRP3 NLRP3 activation, along with processing and release of downstream associated pro-inflammatory cytokines, IL-1β and […]
Brings More Than 30 Years of Pharmaceutical and Biotechnology Leadership Experience Supports Cardurion’s Continued Advancement of Growing Pipeline of Cardiovascular Drug Candidates February 16, 2022 08:00 AM Eastern Standard Time BOSTON–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, […]
MASON, Ohio,–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2021 and full year 2021 financial results. “We achieved several milestones in 2021 including the approval and launch of Hybrid […]
WASHINGTON–(BUSINESS WIRE)–Heart Valve Voice US, a nonprofit patient advocacy organization, is launching a new mobile app for its popular My Valve My Voice patient community. The app, now available for iOS and Android users, is among several initiatives for American Heart Month and Valve Disease Day announced today by the organization. “The […]
Revenue of €2.2 million corresponding to the first sales of Aeson® hearts Aeson® implants expected to resume in October 2022 Available financial resources providing financial visibility until July 2022 Company actively exploring financing options beyond H1 2022 CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total […]
MARLBOROUGH, Mass., Feb. 15, 2022 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced transseptal access solutions as well as guidewires, sheaths and dilators used to support catheter-based left-heart procedures. “The close of this acquisition allows Boston Scientific to integrate the […]
CHICAGO, Feb. 15, 2022 /PRNewswire/ — Cardiosense, Inc., a Chicago-based digital health company building a physiological waveform AI platform to manage cardiac disease, announced today that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device status for its novel algorithm to identify patients at risk of decompensated heart failure. The algorithm analyzes […]
